Equities

ARS Pharmaceuticals Inc

SPRY:NMQ

ARS Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)8.91
  • Today's Change0.09 / 1.02%
  • Shares traded330.12k
  • 1 Year change+45.11%
  • Beta0.8692
Data delayed at least 15 minutes, as of May 30 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

  • Revenue in USD (TTM)10.00k
  • Net income in USD-49.70m
  • Incorporated2016
  • Employees24.00
  • Location
    ARS Pharmaceuticals Inc11682 El Camino Real, Suite 120SAN DIEGO 92130United StatesUSA
  • Phone+1 (858) 771-9307
  • Fax+1 (845) 818-3588
  • Websitehttps://ars-pharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Viridian Therapeutics Inc288.00k-218.13m793.95m96.00--2.07--2,756.78-4.50-4.500.00589.130.0006--2.503,063.83-42.89-55.59-45.38-60.32-----75,737.84-5,678.12----0.0337---82.28-48.16-83.05--15.08--
Cogent Biosciences Inc0.00-212.17m805.54m164.00--4.02-----2.47-2.470.004.420.00----0.00-57.40-49.53-62.27-54.94-------1,684.44----0.00-------37.20--38.48--
Aurinia Pharmaceuticals Inc191.41m-62.56m808.06m300.00--2.26--4.22-0.4363-0.43631.342.500.39530.60087.98638,023.30-12.92-25.97-14.63-28.2488.78---32.69-137.645.05--0.1843--30.95227.9027.88--57.11--
Arcturus Therapeutics Holdings Inc124.53m-107.30m834.89m180.00--3.16--6.70-4.02-4.024.669.810.2799--2.08691,811.10-24.12-19.66-31.37-24.90-----86.16-77.55----0.00---19.0360.31-417.95--14.44--
ARS Pharmaceuticals Inc10.00k-49.70m839.11m24.00--3.74--83,911.29-0.5198-0.51980.00012.320.00004----416.67-19.93-20.37-20.48-21.32-----496,960.00-17,491.75----0.00---97.72---56.75---17.18--
Humacyte Inc0.00-105.70m839.54m183.00--32.10-----1.01-1.010.000.21960.00----0.00-61.38---68.92-------------61.500.4145---100.00---825.83------
Stoke Therapeutics Inc7.85m-108.53m846.95m110.00--5.38--107.96-2.42-2.420.17473.020.0322--31.1971,318.18-44.57-31.62-51.70-33.92-----1,383.40-1,775.50----0.00---29.22---3.59--11.56--
Prime Medicine Inc591.00k-204.50m853.42m234.00--3.50--1,444.03-2.17-2.170.00622.030.0019----2,525.64-65.09---70.51-------34,601.86------0.00-------39.52------
USANA Health Sciences, Inc.900.45m61.94m856.51m1.80k14.031.7111.490.95123.203.2046.5626.251.462.73--500,250.0010.0316.2312.4921.7580.9881.426.888.963.20--0.00260.00-7.77-4.98-8.02-12.764.86--
89bio Inc0.00-165.03m862.83m70.00--1.64-----2.01-2.010.005.360.00----0.00-30.80-45.50-32.70-49.31------------0.0466-------39.37---36.58--
OPKO Health Inc799.60m-252.43m871.24m3.93k--0.6955--1.09-0.3427-0.34271.081.800.38597.536.87203,461.30-12.18-7.14-13.58-8.1432.6334.42-31.56-13.831.58-4.960.2217---14.01-2.7042.49---10.19--
Rapport Therapeutics Inc0.00-51.31m888.81m58.00---------1.45-1.450.005.52------0.00--------------------0.00-------226.57------
Ocular Therapeutix Inc59.84m-115.27m890.61m267.00--2.18--14.88-1.09-1.090.63352.640.17932.232.51224,127.30-34.54-46.70-37.58-54.1890.9989.36-192.62-228.6521.29-9.100.1401--13.4996.60-13.65--26.37--
Immunome Inc12.68m-232.03m894.74m55.00--3.12--70.55-5.49-5.490.42734.780.069----230,600.00-126.15-94.54-148.61-112.66-----1,829.44-1,403.15----0.00-------184.68--29.52--
Data as of May 30 2024. Currency figures normalised to ARS Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

27.25%Per cent of shares held by top holders
HolderShares% Held
RA Capital Management LPas of 31 Mar 202410.86m11.26%
Franklin Advisers, Inc.as of 31 Mar 20242.95m3.06%
The Vanguard Group, Inc.as of 31 Mar 20242.82m2.93%
BlackRock Fund Advisorsas of 31 Mar 20242.36m2.45%
K2 & Associates Investment Management, Inc.as of 31 Mar 20242.22m2.30%
SSgA Funds Management, Inc.as of 31 Mar 20241.60m1.66%
Fidelity Management & Research Co. LLCas of 31 Mar 20241.08m1.12%
Geode Capital Management LLCas of 31 Mar 2024876.67k0.91%
Perceptive Advisors LLCas of 31 Mar 2024867.32k0.90%
Rubric Capital Management LPas of 31 Mar 2024639.20k0.66%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.